好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cortical Oligodendrocyte Gene Networks Regulated by miR-142-3p are Associated with Tauopathy in Mice and Humans
General Neurology
S13 - Advances in General Neurology (2:32 PM-2:40 PM)
004

Using a combination of gene expression profiling and comparative bioinformatics, we examined whether regionally distinct gene profiling could inform how oligodendrocytes contribute to neuropsychiatric disease.

Oligodendrocytes exist in diverse populations that vary in density throughout the central nervous system with a proposed heterogeneity of function including non-myelinating roles. Oligodendrocytes are implicated in multiple neuropsychiatric diseases including dementia. Cortical oligodendrocytes are uniquely positioned to play a key role in neurodegeneration by synchronizing circuit connectivity but specific molecular pathways are presently lacking.

We utilized oligodendrocyte-specific translating ribosome affinity purification and RNA-seq (TRAP-seq) coupled with weighted gene co-expression network analysis (WGCNA) to transcriptionally profile adult mature oligodendrocytes from different regions of the central nervous system in mice to identify and characterize distinct region-specific gene networks.

We identified two gene networks that uniquely define cortical oligodendrocytes and differentially regulate either cortical myelination or synaptic signaling. These two cortical oligodendrocyte gene networks are enriched for genes associated with dementia, including MAPT, and multiple gene targets of the regulatory microRNA, miR-142-3p. Using a combination of TRAP-qPCR, miR-142-3p overexpression in vitro, and miR-142-null mice, we show that miR-142-3p modulates these networks and negatively regulates cortical myelination. In rTg4510 tau-overexpressing mice, a well-studied model of dementia pathogenesis, cortical myelination is compromised, and tau-mediated neurodegeneration is associated with gene co-expression networks that recapitulate both cortical oligodendrocyte gene networks and alter cellular pathways in both the cortex and the hippocampus, a key brain region affected in Alzheimer disease. We further demonstrate these overlapping gene networks from normal cortical mature oligodendrocytes are present and disease-associated in existing datasets from human tauopathies.

Our approach identified two gene networks specific to cortical oligodendrocytes with distinct biologic functions associated with tau-mediated neurodegeneration in both mouse and human. We provide evidence connecting the plastic control of cortical myelination, via miR-142-3p regulation, to human neurodegenerative disease.

Authors/Disclosures
Brent L. Fogel, MD, PhD, FAAN (UCLA Neurology)
PRESENTER
Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for National Ataxia Foundation. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Ataxia Global Initiative. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Today. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Genetics. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Genes. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neuromarkers. The institution of Dr. Fogel has received research support from the National Institutes of Health. The institution of Dr. Fogel has received research support from the National Ataxia Foundation. The institution of an immediate family member of Dr. Fogel has received research support from the National Institutes of Health, the National Science Foundation, and the Department of Defense. The institution of Dr. Fogel has received research support from US Department of Defense .
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Mohammad Ikram (Erasmus MC) The institution of Mohammad Ikram has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BioGen Inc.
No disclosure on file
No disclosure on file
Giovanni Coppola, MD (UCLA) Dr. Coppola has received personal compensation for serving as an employee of Regeneron. Dr. Coppola has received stock or an ownership interest from Regeneron.
No disclosure on file
No disclosure on file
No disclosure on file
Kenneth S. Kosik, MD Dr. Kosik has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Rainwater Foundation. The institution of Dr. Kosik has received research support from National Institute of Health. The institution of Dr. Kosik has received research support from Hillblom Foundation. The institution of Dr. Kosik has received research support from Adelson Medical Foundation. The institution of Dr. Kosik has received research support from Alzheimer Association/Rainwater Foundation. The institution of Dr. Kosik has received research support from Thome Memorial FOundation.
Jason D. Hinman, MD, PhD (David Geffen School of Medicine, UCLA) Dr. Hinman has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Bertoldo, Baker, Carter & Smith. Dr. Hinman has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Koskoff, Koskoff & Bieder. Dr. Hinman has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Matthew Millea, PC. Dr. Hinman has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Popham Law Firm PC. Dr. Hinman has received stock or an ownership interest from Sage Cerebrovascular Diagnostics, Inc.. Dr. Hinman has received research support from NIH. Dr. Hinman has received research support from American Heart Association. Dr. Hinman has received research support from Reneuron. Dr. Hinman has received intellectual property interests from a discovery or technology relating to health care.